Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases
Description
CONCLUSION: In a population with autoimmune or inflammatory diseases at risk of severe COVID-19 unresponsive to vaccination, pre-exposure prophylaxis by tixagevimab/cilgavimab was associated with lower incidence of COVID-19 and no severe infection to